Speaker: John Gribben

0:08:18

CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading?

0:02:23

John Gribben talks on Coronavirus

0:03:14

CAR T-cell therapy: a field moving fast

0:16:13

Round table with Prof. John Gribben and Prof. Stephan Stilgenbauer on CLL

0:12:15

CAR-T vs bispecific antibodies for lymphoma

2:07:37

Watch Prof John G. Gribben discuss the latest #CLL updates from #ASH2024 - https://bit.ly/Y2024-CLL

0:04:10

John Gribben’s ASH 2019 CLL and lymphoma highlights

0:28:18

CLL RC Patient Meeting 4/23/2015 Gribben

0:01:07

Where are we with precision medicine for CLL?

0:16:12

Exploring the potential of CAR-T therapy in CLL

0:09:19

The need for academic and pharmaceutical collaboration in drug development

0:01:46

Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cells

0:03:04

Why are charity-funded early career research fellowships important in leukemia research?

0:05:57

Making CAR T-cells happen in Europe

0:03:14

Prof. Gribben's highlights from ASH 2016

0:12:04

Day 1 round up: CAR T-cell products

0:02:24

Cellular therapies in lymphoma

0:01:51

Celebrating the return of in-person meetings

0:02:43

What can delegates look forward to this week at EHA 2020?

0:07:43

Immunotherapy for NHL: checkpoint inhibitors, considerations & the future

0:03:17

Why do charities need to keep funding research into leukemia and blood cancer in general?

0:03:26

The current status of CLL treatment and how clinical practice will change

0:02:43

Resistance mechanisms of current treatments in CLL

0:15:11

Genetic basis of immune evasion in lymphoid malignancies: more heterogenetity than we think?